What is Enara Bio?
Enara Bio is a biopharmaceutical company dedicated to revolutionizing cancer treatment through the discovery and development of novel Dark Antigens and bispecific T-cell engagers. Their focus on solid tumors and the exploitation of genomic dark matter aims to create transformative therapies for a broad patient population. The company leverages proprietary technology platforms, including EDAPT and EnTiCE, to optimize its therapeutic candidates. Enara Bio's mission is to make a substantial impact in oncology, driven by an experienced team committed to advancing their vision.
How much funding has Enara Bio raised?
Enara Bio has raised a total of $50M across 2 funding rounds:
Other Financing Round
$17.5M
Series B
$32.5M
Other Financing Round (2019): $17.5M with participation from SV Health
Series B (2024): $32.5M led by Samsara BioCapital, M/ventures, SV Health Investors, and RA Capital Management
Key Investors in Enara Bio
Samsara BioCapital
Samsara BioCapital is a venture capital firm focused on investing in and creating transformative therapeutics for patients. They partner with scientists and drug developers to support the next generation of therapeutic breakthroughs in the biopharmaceutical sector.
M/ventures
M/ventures is the investment arm of M/CAPITAL PARTNERS, providing funding and guidance to promising startups across various industries to help them grow and turn bold ideas into successful businesses.
SV Health Investors
SV Health Investors is a specialist investment firm that backs innovative healthcare and life science companies, offering capital, sector expertise, and active support from early growth stages through to scaling and value creation.
What's next for Enara Bio?
With this major enterprise-level funding, Enara Bio is strategically positioned to accelerate its research and development pipeline. The substantial capital will likely be directed towards advancing its lead programs through clinical trials, expanding its scientific team, and further developing its innovative technology platforms. This investment signals a strong belief in Enara Bio's potential to deliver next-generation cancer immunotherapies and address unmet needs in solid tumor treatment, paving the way for future commercialization and market expansion.
See full Enara Bio company page
